Abstract
Mutations in isocitrate dehydrogenase-2 (IDH2) occur in around 5% of patients with myelodysplastic syndromes. Neomorphic activity of mutant IDH2 proteins results in hypermethylation of DNA and histones, leading to blocked haemopoietic differentiation. Enasidenib, an inhibitor of mutated IDH2 proteins, induces responses in patients with IDH2-mutated, relapsed or refractory acute myeloid leukaemia. We aimed to establish the clinical outcomes of enasidenib monotherapy in a subgroup of patients with myelodysplastic syndromes harbouring mutations in IDH2 from the AG221-C-001 trial. The multicentre, open-label, phase 1-2 AG221-C-001 trial enrolled patients with advanced haematological malignancies (2008 WHO criteria) harbouring an IDH2 mutation. The present study is a subgroup analysis of patients with IDH2-mutated myelodysplastic syndromes in the phase 1 dose-escalation and expansion portions of the trial. Patients with myelodysplastic syndromes were aged 18 years or older with an ECOG performance status score of 2 or lower, and were relapsed or refractory to, or ineligible for, standard treatments. Patients received oral doses of enasidenib at 60-300 mg per day in repeated 28-day treatment cycles. In this subgroup analysis, we focu...Continue Reading
Citations
Jun 2, 2020·Expert Review of Anticancer Therapy·Jonathan FeldShyamala C Navada
May 23, 2020·Haematologica·Eva Hellström-LindbergPeter Greenberg
Oct 1, 2020·The New England Journal of Medicine·Mario Cazzola
Aug 30, 2020·Cancers·Ugo TestaElvira Pelosi
Feb 6, 2021·Experimental Biology and Medicine·Zhimei CaiHaiqing Wang
Jan 13, 2021·Cells·Haemin KimKyung-Hyun Park-Min
Jan 30, 2021·Seminars in Hematology·Jesus D Gonzalez-LugoAditi Shastri
Jan 30, 2021·Frontiers in Cell and Developmental Biology·Zhen WeiPing Yi
Mar 8, 2021·Pathology·Charlotte F M HughesRishu Agarwal
Mar 26, 2021·Best Practice & Research. Clinical Haematology·Terra Lasho, Mrinal M Patnaik
Nov 28, 2020·Biochimica Et Biophysica Acta. Molecular Basis of Disease·Gabriela L OliveiraPaulo J Oliveira
Aug 31, 2020·Clinical Lymphoma, Myeloma & Leukemia·Stéphane de Botton
May 19, 2021·Clinical Epigenetics·Tianshu YangYan Wang
May 20, 2021·American Society of Clinical Oncology Educational Book·Robert P HasserjianMrinal M Patnaik
May 29, 2021·Leukemia·Uwe PlatzbeckerThomas Prebet
Jun 17, 2021·Nature Reviews. Clinical Oncology·Christopher J Pirozzi, Hai Yan
Jun 22, 2021·Leukemia & Lymphoma·Lori A RamkissoonJoshua F Zeidner
Jul 2, 2021·Clinical Lymphoma, Myeloma & Leukemia·Matteo Dragani, Stéphane de Botton
Aug 1, 2021·The Annals of Pharmacotherapy·Clement Chung
Aug 4, 2021·Drugs & Aging·Rory M Shallis, Amer M Zeidan
Aug 9, 2021·The Journal of Molecular Diagnostics : JMD·Christina K FerroneMichael J Rauh
Jun 12, 2021·Blood·Jeffrey E Rubnitz, Gertjan J L Kaspers
Oct 11, 2021·British Journal of Haematology·Nina KimKelly J Norsworthy
Sep 3, 2021·Current Opinion in Oncology·Valeria Santini